Alluvi, formerly BI 4744, offers a notable advance in obesity care. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling results in https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/